Improvement of Sexual Function and Sleep Quality in Patients with Atopic Dermatitis Treated with Dupilumab: A Single-Centre Prospective Observational Study
Metadatos
Mostrar el registro completo del ítemAutor
Ureña Paniego, Clara Amanda; Montero Vílchez, Trinidad; Sanabria de la Torre, Raquel; Soto Moreno, Alberto; Molina Leyva, Alejandro; Arias Santiago, Salvador AntonioEditorial
MDPI
Materia
Atopic dermatitis Dupilumab Sexual health
Fecha
2023-01-20Referencia bibliográfica
Ureña-Paniego, C.; Montero-Vílchez, T.; Sanabria-de-la-Torre, R.; Soto-Moreno, A.; Molina-Leyva, A.; Arias-Santiago, S. Improvement of Sexual Function and Sleep Quality in Patients with Atopic Dermatitis Treated with Dupilumab: A Single-Centre Prospective Observational Study. Int. J. Environ. Res. Public Health 2023, 20, 1918. https://doi.org/10.3390/ijerph20031918
Resumen
Atopic dermatitis (AD) is a chronic inflammatory skin disease presenting as xerosis, eczema
and intense pruritus. These symptoms negatively impact patients’ quality of life. However, the
effect of AD on sexual function and sleep quality and how treatment with dupilumab could modify
them have not been explored in depth. The aim of this study is to assess the effects of dupilumab
on sexual and sleep quality in patients with AD. For that purpose, an observational prospective
study was designed. Patients were evaluated at baseline and after 16 weeks of dupilumab treatment.
Disease severity was assessed by Eczema Area and Severity (EASI) and SCORing Atopic Dermatitis
index (SCORAD). Sexual function was evaluated using validated questionnaires, for men via the
International Index of Erectile Dysfunction 5 (IIEF-5) and for women via the Female Sexual Function
Index (FSFI). Sleep impairment was recorded through Pittsburgh Sleep Quality Index (PSQI). Thirtytwo
patients, with a mean age of 30.53 ± 14.48 years old, were included. Regarding sex, 59.8% (20)
were female. Most patients had a severe disease reflected in a mean basal EASI of 23.24 ± 6.74 and a
SCORAD of 54.07 ± 13.89. Clinical scores improved after dupilumab treatment. At baseline, 47.37%
women presented sexual dysfunction and 66.67% men had erectile dysfunction. FSFI improved from
23.51 to 27.93 points (p = 0.008) after dupilumab. Desire, arousal, satisfaction and pain were the
components with great improvement. Women with a great improvement in FSFI showed greater
clinical results and increased quality of life. At first, 96.9% (31/32) of participants presented with poor
sleep quality. After treatment with dupilumab, sleep quality was enhanced and PSQI scores decreased
from 12.8 points at baseline to 7.73 points (p < 0.001). In conclusion, dupilumab is associated with
reduced sexual dysfunction, mainly in women, and sleep quality.





